A novel application of α-glucosyl hesperidin for nanoparticle formation of active pharmaceutical ingredients by dry grinding

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 79, Issue 3, 2011, Pages 559-565

  Tozuka, Yuichi ^a   Imono, Masaaki ^a   Uchiyama, Hiromasa ^a   Takeuchi, Hirofumi ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Glucosyl hesperidin; Blood glucose level; Dissolution rate; Dry grinding; Glibenclamide; Nanoparticle

Indexed keywords

ALPHA GLUCOSYL HESPERIDIN; BEZAFIBRATE; FUROSEMIDE; GLIBENCLAMIDE; GLUCOSE; HESPERIDIN; MEFENAMIC ACID; NANOPARTICLE; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRYSTAL; DISPERSION; DRUG MIXTURE; DRUG SOLUBILITY; GLUCOSE BLOOD LEVEL; GRINDING; NONHUMAN; RAT;

ANIMALS; BLOOD GLUCOSE; DRUG COMPOUNDING; EXCIPIENTS; GLUCOSIDES; GLYBURIDE; HESPERIDIN; HYPOGLYCEMIC AGENTS; MALE; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; POWDER DIFFRACTION; RATS; RATS, WISTAR; SOLUBILITY; SURFACE PROPERTIES; X-RAY DIFFRACTION;

EID: 80053972284     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2011.07.006     Document Type: Article

References (33)

1. W. Yang, K.P. Johnston, and R.O. Williams Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats Eur. J. Pharm. Biopharm. 75 2010 33 41
2. T. Lebhardt, S. Roesler, H.P. Uusitalo, T.s. Kissel, Surfactant-free redispersible nanoparticles in fast-dissolving composite microcarriers for dry-powder inhalation, Eur. J. Pharm. Biopharm., doi: 10.1016/j.ejpb.2010.12. 002.
3. J.C. Zillies, K. Zwiorek, F. Hoffmann, A. Vollmar, and T.J. Anchordoquy Formulation development of freeze-dried oligonucleotide-loaded gelatin nanoparticles Eur. J. Pharm. Biopharm. 70 2008 514 521
4. A.M. Cerdeira, M. Mazzotti, and B. Gander Miconazole nanosuspensions: influence of formulation variables on particle size reduction and physical stability Int. J. Pharm. 396 2010 210 218
5. P. Ruenraroengsak, J.M. Cook, and T.F. Alexander Nanosystem drug targeting: facing up to complex realities J. Control. Release 141 2010 265 276
6. M. Vogt, K. Kunath, and J.B. Dressman Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations Eur. J. Pharm. Biopharm. 68 2008 283 288
7. A. Makhlof, M. Werle, Y. Tozuka, and H. Takeuchi A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa J. Control. Release 149 2011 81 88
8. A. Makhlof, S. Fujimoto, Y. Tozuka, and H. Takeuchi In vitro and in vivo evaluation of WGA-carbopol modified liposomes as carriers for oral peptide delivery Eur. J. Pharm. Biopharm. 77 2011 216 224
9. K. Hironaka, Y. Inokuchi, Y. Tozuka, M. Shimazawa, H. Hara, and H. Takeuchi Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye J. Control. Release 136 2009 247 253
10. S.K. Sahu1, and A.K. Prusty Design and evaluation of a nanoparticulate system prepared by biodegradable polymers for oral administration of protein drugs Pharmazie 65 2010 824 829
11. K. Ohashi, T. Kabasawa, T. Ozeki, and H. Okada One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis J. Control. Release 135 2009 19 24
12. Y. Shono, E. Jantratid, F. Kesisoglou, C. Reppas, and J.B. Dressman Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans Eur. J. Pharm. Biopharm. 76 2010 95 104
13. S. Skolnik, X. Lin, J. Wang, X.H. Chen, T. He, and B. Zhang Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay J. Pharm. Sci. 99 2010 03246 3265
14. D. Heng, K. Ogawa, J.C. David, H.K. Chan, J.A. Raper, L. Ye, and J. Yun Pure drug nanoparticles in tablets: what are the dissolution limitations? J. Nanopart Res. 12 2010 1743 1754
15. V.B. Eerdenbrugh, J. Vermant, J.A. Martens, L. Froyen, J.V. Humbeeck, V.D. Mooter, and P. Augustijns Solubility increases associated with crystalline drug nanoparticles: methodologies and significance Mol. Pharmaceut. 7 2010 1858 1870
16. K. Sigfridsson, A.J. Lundqvist, and M. Strimfors Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development Drug Dev. Ind. Pharm. 35 2009 1479 1486
17. K. Sugano, A. Okazaki, S. Sugimoto, S. Tavornvipas, A. Omura, and T. Mano Solubility and dissolution profile assessment in drug discovery Drug Metab. Pharmacokinet. 22 2007 225 254
18. G. Bucton, and A.E. Beezer The relationship between particle size and solubility Int. J. Pharm. 82 1992 R7 R10
19. A. Mihranyan, and M. Strømme Solubility of fractal nanoparticles Surface Sci. 601 2007 315 319 (Pubitemid 46074080)
20. I. Krycer, and J.A. Hersey Grinding and granulation in a vibratory ball mill Powder Technol. 28 1981 91 95
21. T. Ho, and J.A. Hersey Granulation using the agglomerative phase of comminution Powder Technol. 23 1979 191 195 (Pubitemid 10405066)
22. T. Mizoe, S. Beppu, T. Ozeki, and H. Okada One-step preparation of drug-containing microparticles to enhance the dissolution and absorption of poorly water-soluble drugs using a 4-fluid nozzle spray drier J. Control. Release 120 2007 205 210 (Pubitemid 47058639)
23. R.H. Muller, C. Jacobs, and O. Kayser Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future Adv. Drug Deliv. Rev. 47 2001 3 19 (Pubitemid 32209229)
24. J. Zhang, Y. Tozuka, H. Uchiyama, K. Higashi, K. Moribe, H. Takeuchi, K. Yamamoto, NMR investigation of a novel excipient, α-glicosylhesperidin as a suitable solubilizing agent for poorly water-soluble drugs, J. Pharm. Sci., doi: 10.1002/jps.22606.
25. Y. Tozuka, J. Kishi, and H. Takeuchi Anomalous dissolution property enhancement of naringenin from spray-dried powders with α-glucosyl hesperidin Adv. Powder Technol. 21 2010 305 309
26. H. Uchiyama, Y. Tozuka, H. Imono, and H. Takeuchi Improvement of dissolution and absorption properties of poorly water-soluble drug by preparing spray-dried powders with α-glucosyl hesperidin Int. J. Pharm. 392 2010 101 106
27. H. Uchiyama, Y. Tozuka, H. Imono, and H. Takeuchi Transglycosylated stevia and hesperidin as pharmaceutical excipients: dramatic improvement in drug dissolution and bioavailability Eur. J. Pharm. Biopharm. 76 2010 238 244
28. A.P. Kaplani, and S. Malamataris Preparation and characterisation of a new insoluble polymorphic form of glibenclamide Int. J. Pharm. 195 2000 239 246 (Pubitemid 30089508)
29. H. Kubo, T. Osawa, K. Takashima, and M. Mizobe Enhancement of oral bioavailability and pharmacological effect of by micronization in co-ground mixture with d-mannitol Biol. Pharm. Bull. 19 1997 741 747
30. A. Wongmekiat, Y. Tozuka, T. Oguchi, and K. Yamamoto Formation of fine drug particle by cogrinding with cyclodextrins: Part II. The influence of moisture condition during cogrinding process on fine particle formation Int. J. Pharm. 265 2003 85 93 (Pubitemid 37176949)
31. T. Loftsson, M. Másson, and M.E. Brewster Self-association of cyclodextrins and cyclodextrin complexes J. Pharm. Sci. 93 2004 1091 1099 (Pubitemid 38529683)
32. J. Jinno, N. Kamada, M. Miyake, K. Yamada, T. Mukai, M. Odomi, H. Toguchi, G.G. Liversidge, K. Higaki, and T. Kimura Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs J. Control. Release 111 2006 56 64 (Pubitemid 43289995)
33. K. Sugano Possible reduction of effective thickness of intestinal unstirred water layer by particle drifting effect Int. J. Pharm. 387 2010 103 109